Zelira Therapeutics Limited
ZLDAF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2 |
| % Growth | -99.3% | -68.5% | -80.5% | – |
| Cost of Goods Sold | $1 | $0 | $4 | $7 |
| Gross Profit | -$1 | $0 | -$3 | -$6 |
| % Margin | -122,400.2% | 10.8% | -1,068% | -371% |
| R&D Expenses | $3 | $3 | $1 | $1 |
| G&A Expenses | $2 | $1 | $3 | $6 |
| SG&A Expenses | $0 | $1 | $3 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2 | $2 | $0 |
| Operating Expenses | $3 | $6 | $6 | $8 |
| Operating Income | -$4 | -$6 | -$7 | -$13 |
| % Margin | -602,467.8% | -6,253.9% | -2,159.3% | -870.7% |
| Other Income/Exp. Net | $0 | -$32 | $0 | -$0 |
| Pre-Tax Income | -$4 | -$38 | -$6 | -$14 |
| Tax Expense | $0 | -$1 | $0 | -$1 |
| Net Income | -$4 | -$37 | -$6 | -$12 |
| % Margin | -553,029.3% | -38,513% | -1,850.8% | -775.4% |
| EPS | -0.32 | -3.22 | -0.55 | -1.49 |
| % Growth | 90.1% | -485.5% | 63.1% | – |
| EPS Diluted | -0.32 | -3.22 | -0.55 | -1.49 |
| Weighted Avg Shares Out | 11 | 11 | 10 | 8 |
| Weighted Avg Shares Out Dil | 11 | 11 | 10 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$36 | -$7 | -$12 |
| % Margin | -617,481.4% | -37,409.9% | -2,238.4% | -771.5% |